Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eliscer Guzman

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Annals of Translational Medicine|June 4, 2019
Anti-inflammatory therapy for cardiovascular diseaseConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|August 8, 2018
The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular DiseaseConstantine E Kosmas, Delia Silverio, Christiana Tsomidou, et al.
Therapeutics and Clinical Risk Management|November 5, 2020
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic PotentialConstantine E Kosmas, Alba Muñoz Estrella, Andreas Skavdis, et al.
The Journal of International Medical Research|March 30, 2023
Insulin resistance and cardiovascular diseaseConstantine E Kosmas, Maria D Bousvarou, Christina E Kostara, et al.
Diseases (Basel, Switzerland)|July 18, 2018
Inclisiran: A New Promising Agent in the Management of HypercholesterolemiaConstantine E Kosmas, Alba Muñoz Estrella, Andreas Sourlas, et al.
Annals of Translational Medicine|June 30, 2018
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitusConstantine E Kosmas, Andreas Sourlas, Kyriaki V Bouza, et al.
Annals of Translational Medicine|October 29, 2019
Role of lipoprotein (a) in peripheral arterial diseaseConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Clinical Pharmacology : Advances and Applications|December 18, 2020
Safety and Tolerability of PCSK9 Inhibitors: Current InsightsConstantine E Kosmas, Andreas Skavdis, Andreas Sourlas, et al.
Clinical Pharmacology : Advances and Applications|July 25, 2022
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory HypercholesterolemiaConstantine E Kosmas, Maria D Bousvarou, Andreas Sourlas, et al.
Drugs in Context|April 7, 2018
High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular diseaseConstantine E Kosmas, Ian Martinez, Andreas Sourlas, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Annals of Translational Medicine|June 4, 2019
Anti-inflammatory therapy for cardiovascular diseaseConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|August 8, 2018
The Impact of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular DiseaseConstantine E Kosmas, Delia Silverio, Christiana Tsomidou, et al.
Therapeutics and Clinical Risk Management|November 5, 2020
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic PotentialConstantine E Kosmas, Alba Muñoz Estrella, Andreas Skavdis, et al.
The Journal of International Medical Research|March 30, 2023
Insulin resistance and cardiovascular diseaseConstantine E Kosmas, Maria D Bousvarou, Christina E Kostara, et al.
Diseases (Basel, Switzerland)|July 18, 2018
Inclisiran: A New Promising Agent in the Management of HypercholesterolemiaConstantine E Kosmas, Alba Muñoz Estrella, Andreas Sourlas, et al.
Annals of Translational Medicine|June 30, 2018
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitusConstantine E Kosmas, Andreas Sourlas, Kyriaki V Bouza, et al.
Annals of Translational Medicine|October 29, 2019
Role of lipoprotein (a) in peripheral arterial diseaseConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Clinical Pharmacology : Advances and Applications|December 18, 2020
Safety and Tolerability of PCSK9 Inhibitors: Current InsightsConstantine E Kosmas, Andreas Skavdis, Andreas Sourlas, et al.
Clinical Pharmacology : Advances and Applications|July 25, 2022
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory HypercholesterolemiaConstantine E Kosmas, Maria D Bousvarou, Andreas Sourlas, et al.
Drugs in Context|April 7, 2018
High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular diseaseConstantine E Kosmas, Ian Martinez, Andreas Sourlas, et al.
Pageof 3